• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

AGA recommends early use of biologics in patients with moderate-to-severe Crohn’s disease

Bioengineer by Bioengineer
May 27, 2021
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The American Gastroenterological Association (AGA) issues new clinical guidelines on drug therapy for the management of moderate-to-severe luminal and fistulizing Crohn’s disease.

IMAGE

Credit: American Gastroenterological Association

Bethesda, MD (May 27, 2021) — Crohn’s disease, a type of inflammatory bowel disease (IBD) that causes inflammation (pain and swelling) in the gastrointestinal tract, can cause daily health problems, frequent hospitalizations and surgery when not adequately controlled. While there is no cure for Crohn’s disease, there are treatments that can help patients live a symptom-free life.

After a detailed review of available literature, the American Gastroenterological Association (AGA) has released new clinical guidelines outlining the benefits and risks of each drug currently available to Crohn’s patients. Based on this research, AGA recommends the early introduction of biologics for patients experiencing luminal and fistulizing Crohn’s disease rather than waiting until other treatments fail. These guidelines are published in Gastroenterology, AGA’s official journal.

“With many new drugs entering the market, clinician’s ability to treat patients with Crohn’s disease has improved greatly over the last 20 years,” said lead author Joseph D. Feuerstein, MD, from Beth Israel Deaconess, Boston, Massachusetts. “We hope this new guideline serves as a manual for clinicians in selecting the right therapies for their patients, which should lead to improved patient outcomes and less need for invasive surgery.”

Key guideline recommendations:

    1. Biologics are the most effective drugs for the management of Crohn’s and they should be used early, rather than delaying their use until after failure of mesalamine and/or corticosteroids, in patients with moderate to severe or fistulizing Crohn’s disease. These drugs are antibodies and can more precisely target the immune system which is causing the inflammation in Crohn’s disease.

    a. Anti-tumor necrosis factor (anti-TNF) agents or ustekinumab are recommended and vedolizumab is suggested as a first-line treatment.

    b. In patients who have previously not responded to anti-TNF agents, AGA recommends ustekinumab or vedolizumab.

    c. The biologic natalizumab is no longer recommended due to potential adverse events and the availability of safer treatment options.

Read the AGA Clinical Practice Guideline on the Medical Management of Moderate to Severe Luminal and Fistulizing Crohn’s Disease to review all 25 recommendations.

###

Resources

Guidelines

Technical review

Spotlight (infographic)

Clinical Decision Support Tool

Commentary: Providing the Best Care for Patients with Crohn’s Disease: An Examination of the New AGA Clinical Practice Guideline on the Medical Management of Moderate to Severe Luminal and Fistulizing Crohn’s Disease

Media contact: Courtney Reed, [email protected], 301-272-0025

About the AGA Institute

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. http://www.gastro.org.

AGA is now on Instagram.

Like AGA on Facebook.

Follow us on Twitter @AmerGastroAssn.

Check out our videos on YouTube.

Join AGA on LinkedIn.

Media Contact
Courtney Reed
[email protected]

Tags: GastroenterologyInternal MedicineLiverMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Technology Expert Emphasizes Continued Need for Human Touch in AI-Driven Healthcare Revolution

Technology Expert Emphasizes Continued Need for Human Touch in AI-Driven Healthcare Revolution

August 1, 2025
CCL2-CCR2 Axis Triggers ALS Neuromuscular Denervation

CCL2-CCR2 Axis Triggers ALS Neuromuscular Denervation

August 1, 2025

Saliva Testing Uncovers Early Indicators of Diabetes and Obesity

August 1, 2025

Blocking Bcl-2 Boosts ER Stress Killing Glioblastoma

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Engineered Cellular Communication Enhances CAR-T Therapy Effectiveness Against Glioblastoma

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Technology Expert Emphasizes Continued Need for Human Touch in AI-Driven Healthcare Revolution

CCL2-CCR2 Axis Triggers ALS Neuromuscular Denervation

Supporting Me, Limiting You: Unraveling the Complex Interactions Within Intestinal Microbiota

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.